Copyright
©The Author(s) 2020 Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 14, 2020; 26(30): 4428-4441
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4428
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4428
Table 2 Response and remission at 3 mo of vedolizumab therapy
| Total | Australia | Oxford | P value | |
| Response, n (%) | 208 (79) | 157 (83) | 51 (70) | 0.01 |
| Remission, n (%) | 148 (56) | 104 (55) | 44 (59) | 0.58 |
| Total | Anti-TNF naive | Anti-TNF exposed | P value | |
| Response, n (%) | 208 (79) | 138 (83) | 70 (72) | 0.03 |
| Remission, n (%) | 148 (56) | 109 (66) | 39 (40) | < 0.001 |
| Anti-TNF exposed | Primary LOR | Secondary LOR | P value | |
| Response, n (%) | 70 (72) | 30 (73) | 40 (71) | 0.85 |
| Remission, n (%) | 39 (40) | 16 (39) | 23 (41) | 0.83 |
- Citation: Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441
- URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4428.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4428